Diversify Advisory Services LLC Has $2.90 Million Holdings in Pfizer Inc. $PFE

Diversify Advisory Services LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 177.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 117,466 shares of the biopharmaceutical company's stock after purchasing an additional 75,086 shares during the period. Diversify Advisory Services LLC's holdings in Pfizer were worth $2,898,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of PFE. Handelsbanken Fonder AB increased its stake in shares of Pfizer by 10.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company's stock valued at $59,295,000 after buying an additional 232,528 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Pfizer by 15.7% during the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company's stock valued at $132,365,000 after acquiring an additional 745,213 shares during the period. Vanguard Group Inc. lifted its stake in shares of Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock valued at $13,479,520,000 after acquiring an additional 7,031,162 shares during the period. Leuthold Group LLC bought a new position in Pfizer in the second quarter valued at about $4,887,000. Finally, North Dakota State Investment Board bought a new position in Pfizer in the fourth quarter valued at about $5,348,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on PFE shares. Royal Bank Of Canada raised Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective for the company in a report on Tuesday, June 9th. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. Cantor Fitzgerald reissued a "neutral" rating and set a $27.00 price target on shares of Pfizer in a research note on Monday, July 6th. Weiss Ratings lowered shares of Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, August 17th. Finally, Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $28.28.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Stock Up 0.8%

Shares of Pfizer stock opened at $28.00 on Friday. The business has a fifty day simple moving average of $25.30 and a 200 day simple moving average of $26.25. The stock has a market cap of $159.59 billion, a PE ratio of 36.84 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the firm posted $0.78 earnings per share. The company's quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer's dividend payout ratio (DPR) is currently 226.32%.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source